VANTAGEPOINT INVESTMENT ADVISERS LLCVANTAGEPOINT INVESTMENT ADVISERS LLC

Institutional investor · Portfolio as of Q1 2025

SEC EDGAR SourceSEC Filings

Top Holdings9 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
AGGAGG
ETF

ISHARES TR

3.7M$366M41.7%$91.62+2.08%
20 qtrssince 2020-Q2
Increased
72
TLTTLT
ETF

ISHARES 20 PLUS YEAR TREASURY BD

2.1M$191.3M21.8%$91.28-6.39%
12 qtrssince 2022-Q2
Unchanged
0
SPHYSPHY
ETF

SPDR SERIES TRUST

7.3M$171.1M19.5%$21.260.00%
1 qtr
New
97
IVVIVV
ETF

ISHARES CORE S&P 500 ETF

166,970$93.8M10.7%$437.13+26.45%
20 qtrssince 2020-Q2
Unchanged
0
VCSHVCSH
ETF

VANGUARD S/T CORP BOND ETF

277,700$21.9M2.5%$72.57+2.18%
4 qtrssince 2024-Q2
Increased
82
133,300$10.4M1.2%
4 qtrssince 2024-Q2
Increased
74
IGSBIGSB
ETF

ISHARES 1-5Y INV GRADE CORP

187,500$9.8M1.1%$48.35+7.82%
4 qtrssince 2024-Q2
Increased
73
VTVVTV
ETF

VANGUARD VALUE ETF

55,020$9.5M1.1%$150.28+11.90%
12 qtrssince 2022-Q2
Unchanged
0
VUGVUG
ETF

VANGUARD GROWTH ETF

8,500$3.2M0.4%$34.94+75.93%
11 qtrssince 2022-Q3
Unchanged
0
$877.1M
AUM
9
Positions
Q1 2025
Filing
Rating · 1.5
Quarterly Portfolio Change
+22%Q4'23$749.8M-19%Q1'24$604.4M+20%Q2'24$726.7M+7%Q3'24$779.1M-20%Q4'24$624.1M+41%Q1'25$877.1M
Activity profile
$ moved · Q1'25
New69%Increased31%Decreased0%Exited0%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.1 years
<1Q11%1-4Q0%1-2Y0%2Y+89%

VANTAGEPOINT INVESTMENT ADVISERS LLC manages $877.1M across 9 positions as of Q1 2025. Top holdings: AGG (41.7%), TLT (21.8%), SPHY (19.5%). Fund DNA: Steady Compounder. HoldingsIntel Rating: 1.5/5.0.

Q1 2025 Summary

Added 1 new position, increased 4. Top move: SPHY (NEW, conviction 97). Portfolio: $877M across 9 positions.

Top holdings by portfolio weight

Total AUM$877M
AGG41.73%
TLT21.81%
SPHY19.51%
IVV10.70%
VCSH2.50%
VANGUARD BD 1.19%
IGSB1.12%
VTV1.08%
VUG0.36%

Portfolio allocation by GICS sector

Sectors1
Unknown100.00%

Behavioral investing profile

Checking access…
Steady Compounder- primarily Unknown
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track Record85
Conviction49
Concentration51
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
4Q
VUGVUGVANGUARD GROWTH ETF
Q3 2025 Q2 2026+6.8M shares+$581.2M
3Q
AVEMAVEMAVANTIS EMERGING MARKETS EQ
Q4 2025 Q2 2026+126,777 shares+$60.7M
2Q
VWOVWOVANGUARD FTSE EMERGING MARKETS
Q1 2026 Q2 2026+521,392 shares+$44.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used